Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

SARS-CoV-2 Iota variant

From Wikipedia, the free encyclopedia
Variant of the SARS-Cov-2 virus first identified in New York City

Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal
Main article:Variants of SARS-CoV-2

Iota variant,[1] also known aslineage B.1.526, is one of thevariants ofSARS-CoV-2, the virus that causesCOVID-19. It was first detected inNew York City in November 2020. The variant has appeared with two notable mutations: the E484K spike mutation, which may help the virus evade antibodies, and the S477N mutation, which helps the virus bind more tightly to human cells.[2]

By February 2021, it had spread rapidly in the New York region and accounted for about one in four viral sequences.[3][4] By 11 April 2021, the variant had been detected in at least 48 U.S. states and 18 countries.[5][6]

Under the simplified naming scheme proposed by theWorld Health Organization, B.1.526 has been labeledIota variant, and is considered avariant of interest (VOI), but not yet avariant of concern.[7]

Mutations

[edit]

The Iota (B.1.526) genome contains the following amino-acid mutations, all of which are in the virus'sspike protein code: L5F, T95I, D253G, E484K, D614G and A701V.[8]

  • Amino acid mutations of SARS-CoV-2 Iota variant plotted on a genome map of SARS-CoV-2 with a focus on the spike.[9]
    Amino acid mutations of SARS-CoV-2 Iota variant plotted on a genome map of SARS-CoV-2 with a focus on the spike.[9]

History

[edit]

The increase of the Iota variant was captured by researchers atCaltech by scanning for mutations in a database known asGISAID, a global science initiative that has documented over 700,000 genomic sequences of SARS-CoV-2.[10][11]

The proportion of USA cases represented by the Iota variant had declined sharply by the end of July 2021 as theDelta variant became dominant.[12]

Statistics

[edit]
Cases by country (Updated as of 16 January 2024) GISAID[13]
CountryConfirmed casesLast Reported Case
 USA45,98524 June 2021
 Ecuador16810 June 2021
 Canada158
 Spain11917 June 2021
 Colombia11524 May 2021
 Aruba10310 June 2021
 Germany5622 June 2021
 Mexico5011 June 2021
 United Kingdom4316 May 2021
 Sint Maarten1727 May 2021
 Ireland137 May 2021
  Switzerland1217 May 2021
 Chile1112 May 2021
 Denmark931 May 2021
 Israel926 April 2021
 Suriname910 May 2021
 Argentina826 April 2021
 Belgium818 April 2021
 Dominican Republic810 June 2021
 France825 May 2021
 Lithuania828 May 2021
 Singapore74 April 2021
 Australia621 May 2021
 Italy64 May 2021
 Luxembourg65 March 2021
 Costa Rica521 May 2021
 Netherlands519 April 2021
 Russia54 June 2021
 Croatia49 February 2021
 Japan47 May 2021
 South Korea414 April 2021
 Sweden414 May 2021
 Turkey44 May 2021
 Malta421 December 2020
 India324 March 2021
 Dominica315 January 2021
 Slovenia318 May 2021
 Austria222 April 2021
 Ghana220 March 2021
 Grenada217 January 2021
 Indonesia28 January 2021
 Jamaica22 February 2021
 Liberia214 May 2021
 Portugal24 March 2021
 Romania217 April 2021
 Anguilla121 April 2021
 Antigua and Barbuda13 May 2021
 British Virgin Islands125 January 2021
 Cayman Islands115 April 2021
 China1
 Curacao130 April 2021
 Finland114 March 2021
 Guadeloupe19 March 2021
 New Zealand116 March 2021
 Poland131 March 2021
 Turks and Caicos Islands122 March 2021
 Venezuela18 May 2021
 World (57 countries)Total:46,589Total as of 11 August 2021

See also

[edit]

References

[edit]
  1. ^"Tracking SARS-CoV-2 variants".www.who.int. RetrievedJune 1, 2021.
  2. ^Barton, Michael I; MacGowan, Stuart A; Kutuzov, Mikhail A; Dushek, Omer; Barton, Geoffrey John; van der Merwe, P Anton (August 26, 2021). Fouchier, Ron AM; Van der Meer, Jos W; Fouchier, Ron AM (eds.)."Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics".eLife.10 e70658.doi:10.7554/eLife.70658.ISSN 2050-084X.PMC 8480977.PMID 34435953.
  3. ^Stieb, Matt; Rosa-Aquino, Paola (March 21, 2021)."Everything We Know About the Coronavirus Variant Spreading in New York City".Intelligencer. RetrievedApril 10, 2021.
  4. ^Mandavilli, Apoorva (February 24, 2021)."A New Coronavirus Variant Is Spreading in New York, Researchers Report".The New York Times.ISSN 0362-4331. RetrievedApril 10, 2021.
  5. ^"outbreak.info".outbreak.info. RetrievedApril 10, 2021.
  6. ^"PANGO lineages Lineage B.1.526".cov-lineages.org. April 22, 2021. Archived fromthe original on April 22, 2021. RetrievedApril 22, 2021.
  7. ^"Tracking SARS-CoV-2 variants".www.who.int. RetrievedJune 1, 2021.
  8. ^"SARS-CoV-2 Variant Classifications and Definitions".CDC.gov. Centers for Disease Control and Prevention. February 11, 2020. RetrievedJuly 5, 2021.
  9. ^"Spike Variants: Iota variant, aka B.1.526".covdb.stanford.edu.Stanford University Coronavirus Antiviral & Resistance Database. July 1, 2021. RetrievedJuly 5, 2021.
  10. ^Corum, Jonathan; Zimmer, Carl (February 9, 2021)."Coronavirus Variants and Mutations".The New York Times.ISSN 0362-4331. RetrievedApril 10, 2021.
  11. ^West, Anthony P.; Barnes, Christopher O.; Yang, Zhi; Bjorkman, Pamela J. (February 23, 2021)."SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape".bioRxiv 2021.02.14.431043.doi:10.1101/2021.02.14.431043.PMC 8077570.PMID 33907745.S2CID 231981267.
  12. ^SARS-CoV-2 sequences by variant, Jul 26, 2021, USA Our World in Data
  13. ^"GISAID - hCov19 Variants".www.gisaid.org. RetrievedJuly 2, 2021.
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Retrieved from "https://en.wikipedia.org/w/index.php?title=SARS-CoV-2_Iota_variant&oldid=1309278538"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp